|
Canada-49280-CEILING CONTRACTORS företaget Kataloger
|
Företag Nyheter:
- Biologics for eosinophilic oesophagitis: a systematic review and meta . . .
Biologics targeting IL-5 have been exploited and investigated in EoE and other non-EoE EGIDs, such as mepolizumab, reslizumab, and benralizumab Mepolizumab and reslizumab bind directly to the IL-5 molecule, interfering with its attachment to IL-5Rα expressed on the eosinophil cell surface
- Current state of biologics in treating eosinophilic esophagitis
Eosinophilic esophagitis (EoE) is a T2 eosinophil-rich inflammation for which only biologic therapy is approved by the Food and Drug Administration Anti–interleukin (IL)-4Rα (dupilumab) is approved for EoE
- Biologics in the Treatment of Eosinophilic Esophagitis: Ready for Use?
Therapies that are easy to administer, regulate underlying type 2 inflammation, and reduce disease progression in EoE are desirable This review focuses on dupilumab, which is the only Food and Drug Administration (FDA) approved biologic therapy for EoE
- Biologics in eosinophilic esophagitis - PubMed
This review serves to summarize safety and efficacy of monoclonal antibodies in treatment of EoE Recent findings: There has been an increasing number of biologics under consideration for EoE and several that have undergone clinical trials mAbs that target specific effectors involved in the disease may offer additional clinical and histologic
- Biologics in Eosinophilic Esophagitis — Ready for Prime Time?
Eosinophilic esophagitis is an immune-mediated, chronic, inflammatory disease of the esophagus that was first recognized as a distinct entity less than three decades ago 1 The
- Consumer’s Guide to Biologics for Eosinophilic Esophagitis
Wondering if you should take a biologic medication to treat eosinophilic esophagitis? Here’s what you should know about this innovative drug class
- DUPIXENT® (dupilumab) For Eosinophilic Esophagitis
DUPIXENT helps control an underlying inflammation that contributes to EoE symptoms It’s a great feeling knowing that I no longer have to think about my EoE every second of every day DUPIXENT Patient Ambassador Individual results may vary
- Eosinophilic esophagitis: promising therapy, biomarkers, and assessment . . .
Biologics and other novel therapies are needed for treatment of EoE because of suboptimal response rates to proton pump inhibitors (PPIs), most topical steroids, and dietary approaches, said Evan S Dellon MD, MPH, professor of medicine at University of North Carolina Chapel Hill School of Medicine
- Current state of biologics in treating eosinophilic esophagitis
Biologics have been used as investigational therapies for EoE in clinical studies over the years, based on earlier work that identified key cytokines and mediators of eosinophilic inflammation and, more recently, type 2 inflammation that underlie EoE pathogenesis
- Eosinophilic Esophagitis: Advanced Treatments - WebMD
In May 2022, the FDA approved the first biologic drug, dupilumab (Dupixent), to treat EoE in people over 12 Dupilumab is a type of drug called a monoclonal antibody You take it as an
|
|